Clarity’s cutting edge imaging: Fibrosis
Fibrosis is the hardening or scarring of various organs, such as the heart, lung, liver and kidney, which is usually a result of abnormal wound healing to tissue injury. It usually leads to an excessive deposition of extracellular matrix components, predominantly collagen. As a result, it leads to organ stiffness and ultimately, organ failure.
There are currently a number of treatments for patients with various forms of fibrosis, however many patients still progress to end-stage organ failure due to challenges in early diagnosis and inability of the existing treatments to directly target the build-up of fibrosis.
Clarity is at the forefront of nuclear medicine based fibrosis imaging. The theranostic approach allows fibrotic tissue to be detected and measured using non-invasive imaging of the organ of interest. The patient can then be treated with drugs in development aiming to reduce or reverse fibrosis. A follow up image will then allow the reduction or reversal to be quantified more accurately and in a shorter time period than traditional diagnostic measures, such as biopsy.
With an aim of advancing this field, a research group at Baker IDI Heart and Diabetes Institute and Monash University led by Prof. Christoph Hagemeyer has developed a non-invasive imaging product for use as a companion diagnostic to select patients or monitor therapy. The product targets fibrotic tissue, including pulmonary and cardiac fibrosis. The product radiolabelled with Clarity’s Copper-64 chelator (MECOSAR) can be used to monitor fibrosis with high accuracy and potentially determine changes in fibrosis.
We are hoping to progress our collaboration and further advance Clarity’s expertise in the field of fibrosis imaging and therapy, which we can offer to prospective clients.
Clarity Pharmaceuticals is a client of ATP Innovations, Australia’s leading business incubator.